- Institution: Stanford Univ Med Ctr Lane Med Lib/Periodical Dept/Rm L109
- Sign In as Member / Individual
Anti-HIV-1 Therapeutics: From FDA-approved Drugs to Hypothetical Future Targets
Table 1.
Classes of Anti-HIV-1 Therapeutics: From FDA-approved Drugs to Hypothetical Future Targets
| Class/Target | Example | |
|---|---|---|
| 1Date of FDA approval | ||
| FDA Approved | ||
| Reverse Transcriptase (RT) inhibitors | ||
| Nucleoside analog RT inhibitors (NRTI) | AZT (zidovudine) (1987)1 | |
| Non-nucleoside RT inhibitors (NNRTI) | Nevirapine (1996) | |
| Protease (PR) inhibitors | Saquinavir (1995) | |
| Entry/fusion inhibitors | ||
| Gp41-based | T20 (Enfuvirtide) (2003) | |
| CCR5-based | Maraviroc (2007) | |
| Integrase (IN) inhibitors | Raltegravir (2007) | |
| In Clinical Trials | ||
| Gag-processing-based maturation inhibitors | Bevirimat | |
| Under Development | ||
| RNaseH inhibitors | ||
| Capsid (CA)-based maturation inhibitors | ||
| Budding inhibitors | ||
| LEDGF-based inhibitors | ||
| Vpu/tetherin-based inhibitors | ||
| Vif/APOBEC3G-based inhibitors | ||
| CA/TRIM5α-based inhibitors | ||
